Trial Profile
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 02 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Aug 2023.
- 10 Sep 2021 Status changed from recruiting to active, no longer recruiting.